Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE.
Mu-Mosley H, et al. Among authors: park jy.
Oncoimmunology. 2024 May 9;13(1):2351255. doi: 10.1080/2162402X.2024.2351255. eCollection 2024.
Oncoimmunology. 2024.
PMID: 38737792
Free PMC article.
Clinical Trial.